Program
tigulixostat
Also written as “Tigulixostat”, “LC350189 formulated capsule” and “IBI128”.
Its studies are mostly in Gout · Hyperuricemia, led by 2 companies.
Drug pageTigulixostat: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LG Chemits history only | 80 open or running | phase 3since Oct 16, 2022 | May 19, 2011 | none ahead |
| Innovent Biologics | 21 open or running | phase 3since Feb 3, 2026 | Jul 2, 2024 | Apr 30, 2027phase 3 · NCT07414394 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Innovent Biologics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 19, 2020Named tigulixostatINNProposed as its International Nonproprietary Name in WHO's List 124 · before, IBI128
- Jul 2, 2024First study: phase 2 study in GoutFirst studyNCT06501534 · 84 enrolled · China
- Feb 3, 2026Phase 3 study in GoutPhase 3 reachedNCT07414394 · 600 enrolled · China
Ahead
- Apr 30, 2027Primary completion: phase 3 study in GoutNCT07414394
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Innovent Biologics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07414394Gout · China | 3 | Active, not recruiting | Apr 30, 2027 | 600 |
| NCT06501534Gout · China | 2 | Completed | Dec 13, 2024 | 84 |
How it is read
Names in the registry
- “Tigulixostat”, 4 entries
- “LC350189 formulated capsule”, 1 entry
- “IBI128”, 1 entry
- “LC350189 200mg”, 1 entry
- “LC350189 600mg”, 1 entry
Codes read as this program: IBI128.
Conditions, from the studies’ own filings
- Gout, 8 studies
- Hyperuricemia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.